Literature DB >> 3358893

Adverse reactions to the non-drug constituents of nebuliser solutions.

R Beasley1, P Rafferty, S T Holgate.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3358893      PMCID： PMC1386351          DOI： 10.1111/j.1365-2125.1988.tb03305.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  36 in total

1.  THE POTENTIAL ROLE OF INHALATION THERAPY EQUIPMENT IN NOSOCOMIAL PULMONARY INFECTION.

Authors:  J A REINARZ; A K PIERCE; B B MAYS; J P SANFORD
Journal:  J Clin Invest       Date:  1965-05       Impact factor: 14.808

2.  Serratia marcescens infections from inhalation therapy medications: nosocomial outbreak.

Authors:  C V Sanders; J P Luby; W G Johanson; J A Barnett; J P Sanford
Journal:  Ann Intern Med       Date:  1970-07       Impact factor: 25.391

3.  Nebulizer contamination in a burn unit.

Authors:  A H Morris
Journal:  Am Rev Respir Dis       Date:  1973-05

4.  Asthma induced by adrenergic aerosols.

Authors:  R E Reisman
Journal:  J Allergy       Date:  1970-09

5.  A hospital outbreak of Klebsiella pneumonia from inhalation therapy with contaminated aerosol solutions.

Authors:  J J Mertz; L Scharer; J H McClement
Journal:  Am Rev Respir Dis       Date:  1967-03

6.  Paradoxic bronchospasm after inhalation of isoptroterenol.

Authors:  J Trautlein; J Allegra; J Field; M Gillin
Journal:  Chest       Date:  1976-12       Impact factor: 9.410

7.  Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide.

Authors:  D Sheppard; W S Wong; C F Uehara; J A Nadel; H A Boushey
Journal:  Am Rev Respir Dis       Date:  1980-12

8.  The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma.

Authors:  K A Miszkiel; R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

9.  Exercise increases sulfur dioxide-induced bronchoconstriction in asthmatic subjects.

Authors:  D Sheppard; A Saisho; J A Nadel; H A Boushey
Journal:  Am Rev Respir Dis       Date:  1981-05

10.  Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water.

Authors:  L Allegra; S Bianco
Journal:  Eur J Respir Dis Suppl       Date:  1980
View more
  9 in total

1.  A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions.

Authors:  Q A Summers; M R Nesbit; R Levin; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.

Authors:  Heather S Tomlinson; Sarah A Corlett; Martin B Allen; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.

Authors:  M L Everard; S G Devadason; P N Le Souëf
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

4.  Effect of preservative on the efficacy of terbutaline nebuliser solution in atopic asthma.

Authors:  C K Lai; C H Chan
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 5.  In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Lucy E A Hardaker; Ross H M Hatley
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

6.  Effect of terbutaline on bronchoconstriction induced by nebulised pentamidine.

Authors:  T R Leigh; J Wiggins; B G Gazzard; J V Collins
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

7.  Survey of colourings and preservatives in drugs.

Authors:  I Pollock; E Young; M Stoneham; N Slater; J D Wilkinson; J O Warner
Journal:  BMJ       Date:  1989-09-09

8.  Inhaled antibodies: formulations require specific development to overcome instability due to nebulization.

Authors:  Héloïse Audat; Nathalie Heuzé-Vourc'h; Alexie Mayor; Béatrice Thibert; Sylvain Huille; Renaud Respaud
Journal:  Drug Deliv Transl Res       Date:  2021-03-25       Impact factor: 4.617

9.  Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.

Authors:  Wolfgang Kamin; Astrid Schwabe; Irene Krämer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.